Urinary PCA3 as a predictor of prostate cancer in a cohort of 3,073 men undergoing initial prostate biopsy

Journal of Urology

Volumn 191, Issue 6, 2014, Pages 1743-1748

  Chevli, K Kent ^a,b   Duff, Michael ^a,b   Walter, Peter ^a,b   Yu, Changhong ^c   Capuder, Brian ^c   Elshafei, Ahmed ^c   Malczewski, Stephanie ^a,b   Kattan, Michael W ^c   Jones, J Stephen ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b Western New York Urology Associ LLC   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

human; prostate cancer antigen 3; prostate specific antigen; prostatic neoplasms

Indexed keywords

PROSTATE CANCER ANTIGEN 2; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3; PROSTATE CANCER ANTIGEN 3, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CANCER DIAGNOSIS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; FAMILY HISTORY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE VOLUME; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; DISEASE SEVERITY; GROUPS BY AGE; RISK FACTOR; AGED; BIOPSY; CANCER GRADING; CLINICAL TRIAL; FOLLOW UP; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATE TUMOR; URINE;

AGED; ANTIGENS, NEOPLASM; BIOPSY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84900403208     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.12.005     Document Type: Article

References (21)

1. G.L. Andriole, R.L. Grubb, and S.S. Buys et al. Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310
2. M.J. Barry Screening for prostate cancer-the controversy that refuses to die N Engl J Med 360 2009 1351
3. F.H. Schroder, J. Hugosson, and M.J. Roobol et al. Prostate cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981
4. J. Hugosson, S. Carlsson, and G. Aus et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725
5. M.J. Bussemakers, A. van Bokhoven, and G.W. Verhaegh et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975
6. J.B. de Kok, G.W. Verhaegh, and R.W. Roelofs et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors Cancer Res 62 2002 2695
7. S.M. Aubin, J. Reid, and M.J. Sarno et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial J Urol 184 2010 1947
8. L.S. Marks, Y. Fradet, and I.L. Deras et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 2007 532
9. A. de la Taille, J. Irani, and M. Graefen et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions J Urol 185 2011 2119
10. A. Ochiai, K. Okihara, and K. Kamoi et al. Prostate cancer gene 3 urine assay for prostate cancer in Japanese men undergoing prostate biopsy Int J Urol 18 2011 200
11. H. Nakanishi, J. Groskopf, and H.A. Fritsche et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance J Urol 179 2008 1804
12. G. Ploussard, X. Durand, and E. Xylinas et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance Eur Urol 59 2011 422
13. V. Vlaeminck-Guillem, M. Devonec, and M. Colombel et al. Urinary PCA3 score predicts prostate cancer multifocality J Urol 185 2011 1234
14. E.J. Whitman, J. Groskopf, and A. Ali et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume J Urol 180 2008 1975
15. I.L. Deras, S.M. Aubin, and A. Blase et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587
16. A. Haese, A. de la Taille, and H. van Poppel et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081
17. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10
18. M.R. Cooperberg, J.M. Broering, and P.W. Kantoff et al. Contemporary trends in low risk prostate cancer: risk assessment and treatment J Urol 178 suppl. 2007 S14
19. D. Hessels, M. van Gils, and O. van Hooij et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathologic characteristics of prostate cancer Prostate 70 2010 10
20. F.K. Chun, A. de la Taille, and H. van Poppel et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram Eur Urol 56 2009 659
21. M. Auprich, F.K. Chun, and J.F. Ward et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging Eur Urol 59 2011 96